Two-Year Outcomes of Infants with Stage 2 or Higher Retinopathy of Prematurity: Results from a Large Multicenter RegistryFunding This study was funded by the Center for Research, Education, Quality, and Safety at MEDNAX, Inc.
17 April 2019
09 July 2019
03 September 2019 (online)
Objective To define the incidence of ophthalmologic morbidities in the first 2 years of life among infants diagnosed with stage 2 or higher retinopathy of prematurity (ROP).
Study Design We prospectively enrolled premature infants with stage 2 or higher ROP. The infants were followed up for 2 years, and we report on data collected from outpatient ophthalmology and primary care visits.
Results We enrolled 323 infants who met inclusion criteria, of which 112 (35%) received treatment with laser surgery (90) or bevacizumab (22). Two-year follow-up was available for 292 (90%) of the cohort. The most common ophthalmologic conditions at follow-up were hyperopia (35%), astigmatism (30%), strabismus (21.9%), myopia (19.2%), anisometropia (12%), and amblyopia (12%). Severe ophthalmologic morbidities such as retinal detachment and cataracts were rare, but occurred in both treated and untreated infants. Overall, 22.6% of the infants were wearing glasses at 2 years, including 8.5% of the untreated infants.
Conclusion Patients with stage 2 or higher ROP remain at significant risk for ophthalmological morbidity through 2 years of age. Infants with regression of subthreshold ROP who do not require treatment represent an underrecognized population at long-term ophthalmological risk.
ClinicalTrials.gov Identifier NCT01559571.
MEDNAX ROP Registry Investigators
William Archer, MD, Texas Health Resources–Presbyterian Hospital Dallas (Dallas, TX); Barbara Carr, MD, St. Luke's Hospital of Kansas City (Kansas City, MO); Bradlee Drabant, MD, Spring Valley Hospital; Summerlin Hospital Medical Center; Valley Hospital Medical Center (Las Vegas, NV); Jay Kothadia, MD, Novant Health Presbyterian Medical Center (Charlotte, NC); Martha Manar, MD, Northside Hospital (Atlanta, GA); Joe Mendiola Jr., MD, McAllen Medical Center (McAllen, TX); Renuka K. Reddy, MD, Texas Health Resources–Presbyterian Hospital Plano (Plano, TX); David Riley, MD, MBA, Cook Children's Medical Center (Fort Worth, TX); Jayesh Shah, MD, Charleston Area Medical Center (Charleston, WV); Mustafa Suterwala, MD, Baylor University Medical Center (Dallas, TX); Vivek Vijayamadhavan, MD, Methodist Children's Hospital (San Antonio, TX); Kelly Von Herbulis, NNP, Memorial Health University Medical Center (Savannah, GA); David Wells, MD, Greenville Memorial Hospital (Greenville, SC); Robert D. White, MD, Memorial Hospital South Bend (South Bend, IN).
Janna Benston, RN, MSN, Northside Hospital (Atlanta, GA); Katrina Grier, RNC-NIC, Northside Hospital (Atlanta, GA); Sheryl Hollander, RN, BSN, Novant Health Presbyterian Medical Center (Charlotte, NC); Mashelle Monhaut, MSN, NNP-BC, Memorial Hospital South Bend (South Bend, IN); Denise P. Smith, BSN, RNC-LRN, RRT-NPS, Winnie Palmer Hospital for Women & Babies (Orlando, FL); Vivian Vargas-Brown, Pediatrix Medical Group of Nevada (Las Vegas, NV). Administrative support was provided by: Carole Benson, Jaclyn Cohen, Nalina Fisher, Theresa Katich, Kathy McCarty, Octavia Reed, Vernice Vixamar, and Shannon Weeks.
- 1 Schmidt B, Roberts RS, Davis PG. , et al; Caffeine for Apnea of Prematurity (CAP) Trial Investigators. Prediction of late death or disability at age 5 years using a count of 3 neonatal morbidities in very low birth weight infants. J Pediatr 2015; 167 (05) 982-986
- 2 Darlow BA, Lui K, Kusuda S. , et al; International Network for Evaluating Outcomes of Neonates. International variations and trends in the treatment for retinopathy of prematurity. Br J Ophthalmol 2017; 101 (10) 1399-1404
- 3 Adams GG, Bunce C, Xing W. , et al. Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk. BMJ Open 2017; 7 (03) e013366
- 4 Walz JM, Bemme S, Pielen A. , et al; Retina.net ROP Registry. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol 2016; 94 (08) e744-e752
- 5 Adams M, Bassler D, Bucher HU. , et al; Swiss Neonatal Network and the Vermont Oxford Network. Variability of very low birth weight infant outcome and practice in Swiss and US neonatal units. Pediatrics 2018; 141 (05) e20173436
- 6 Fierson WM. ; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131 (01) 189-195
- 7 Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS 2012; 16 (06) 501-507
- 8 Solebo AL, Teoh L, Rahi J. Epidemiology of blindness in children. Arch Dis Child 2017; 102 (09) 853-857
- 9 Zepeda-Romero LC, Barrera-de-Leon JC, Camacho-Choza C. , et al. Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city, Mexico. Br J Ophthalmol 2011; 95 (11) 1502-1505
- 10 Kimyon S, Mete A. Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1. Ophthalmologica 2018; 240 (02) 99-105
- 11 Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018; 1: CD009734
- 12 Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP. Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 2017; 48 (03) 255-259
- 13 Wallace DK, Kraker RT, Freedman SF. , et al; Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol 2017; 135 (06) 654-656
- 14 Mintz-Hittner HA, Kuffel Jr RR. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28 (06) 831-838
- 15 Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 2016; 123 (09) 1845-1855
- 16 Morin J, Luu TM, Superstein R. , et al; Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016; 137 (04) e20153218
- 17 Holmström GE, Källen K, Hellström A. , et al. Ophthalmologic outcome at 30 months' corrected age of a prospective Swedish cohort of children born before 27 weeks of gestation: the extremely preterm infants in Sweden study. JAMA Ophthalmol 2014; 132 (02) 182-189
- 18 Hellgren KM, Tornqvist K, Jakobsson PG. , et al. Ophthalmologic outcome of extremely preterm infants at 6.5 years of age: Extremely Preterm Infants in Sweden Study (EXPRESS). JAMA Ophthalmol 2016; 134 (05) 555-562
- 19 Piermarocchi S, Bini S, Martini F. , et al. Predictive algorithms for early detection of retinopathy of prematurity. Acta Ophthalmol 2017; 95 (02) 158-164
- 20 Eckert GU, Fortes Filho JB, Maia M, Procianoy RS. A predictive score for retinopathy of prematurity in very low birth weight preterm infants. Eye (Lond) 2012; 26 (03) 400-406
- 21 Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol 2018; 63 (05) 618-637
- 22 Askie LM, Darlow BA, Finer N. , et al; Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration. JAMA 2018; 319 (21) 2190-2201
- 23 Freitas AM, Mörschbächer R, Thorell MR, Rhoden EL. Incidence and risk factors for retinopathy of prematurity: a retrospective cohort study. Int J Retina Vitreous 2018; 4: 20
- 24 Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; (03) CD004863
- 25 Manzoni P, Memo L, Mostert M. , et al. Use of erythropoietin is associated with threshold retinopathy of prematurity (ROP) in preterm ELBW neonates: a retrospective, cohort study from two large tertiary NICUs in Italy. Early Hum Dev 2014; 90 (Suppl. 02) S29-S33
- 26 Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 2005; 5 (01) 18
- 27 Azami M, Jaafari Z, Rahmati S, Farahani AD, Badfar G. Prevalence and risk factors of retinopathy of prematurity in Iran: a systematic review and meta-analysis. BMC Ophthalmol 2018; 18 (01) 83
- 28 Campbell JP, Ryan MC, Lore E. , et al; Imaging & Informatics in Retinopathy of Prematurity Research Consortium. Diagnostic discrepancies in retinopathy of prematurity classification. Ophthalmology 2016; 123 (08) 1795-1801
- 29 Stoll BJ, Hansen NI, Bell EF. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
- 30 Ellsbury DL, Clark RH, Ursprung R, Handler DL, Dodd ED, Spitzer AR. A multifaceted approach to improving outcomes in the NICU: the Pediatrix 100 000 Babies Campaign. Pediatrics 2016; 137 (04) pii: e20150389
- 31 Horbar JD, Edwards EM, Greenberg LT. , et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr 2017; 171 (03) e164396
- 32 Lyu J, Zhang Q, Chen CL. , et al. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci 2017; 58 (03) 1719-1725
- 33 Barry GP, Tauber K, Emmanuel G, Horgan MJ, Simon JW. The effectiveness of policy changes designed to increase the attendance rate for outpatient retinopathy of prematurity (ROP) screening examinations. J AAPOS 2013; 17 (03) 296-300
- 34 Aprahamian AD, Coats DK, Paysse EA, Brady-Mccreery K. Compliance with outpatient follow-up recommendations for infants at risk for retinopathy of prematurity. J AAPOS 2000; 4 (05) 282-286
- 35 Attar MA, Gates MR, Iatrow AM, Lang SW, Bratton SL. Barriers to screening infants for retinopathy of prematurity after discharge or transfer from a neonatal intensive care unit. J Perinatol 2005; 25 (01) 36-40